Form 4: Stoke Therapeutics CMO Sells Shares Under 10b5-1 Plan

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, reported a future sale of 5,501 shares of common stock for approximately $19.87 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Barry Ticho, Chief Medical Officer of Stoke Therapeutics, Inc. (STOK), reported a planned sale of common stock.
• The transaction involves the disposition of 5,501 shares of common stock.
• The shares are to be sold at a weighted average price of $19.8737 per share, with individual sales prices expected to range from $19.54 to $20.34 per share.
• The transaction is scheduled to be executed on September 2, 2025.
• This sale is conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ticho on December 11, 2024.
• Following this planned transaction, Mr. Ticho will beneficially own 18,469 shares of common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a pre-scheduled insider stock sale under a Rule 10b5-1 plan, which is a routine disclosure and generally viewed as neutral to slightly negative, as it's a planned liquidation rather than a reaction to new information.

Negatives

• An insider (Chief Medical Officer) is selling 5,501 shares of company stock, which can sometimes be perceived negatively by the market, although this is mitigated by the pre-planned nature under a Rule 10b5-1 plan.

Future Outlook

No specific future outlook or guidance for the company is provided in this insider transaction report.

Industry Context

This filing reports a routine insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may interpret the insider sale as a slight negative, though this is mitigated by the pre-arranged nature of the Rule 10b5-1 plan. The sale represents a relatively small portion of the company's overall outstanding shares.

Next Steps

• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the reported range.

Key Dates

Recommendation

The reported insider sale by the Chief Medical Officer was executed under a pre-arranged Rule 10b5-1 trading plan, adopted several months prior to the transaction date. Such planned sales are generally not indicative of a change in the company's fundamental outlook or a lack of confidence, but rather a personal financial planning event. Therefore, this specific filing does not provide sufficient new information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Stoke Therapeutics, STOK, Insider Trading, Form 4, Barry Ticho, Chief Medical Officer, Stock Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals